Annual CFO
-$43.75 M
+$5.29 M+10.79%
31 December 2023
Summary:
Leap Therapeutics annual cash flow from operations is currently -$43.75 million, with the most recent change of +$5.29 million (+10.79%) on 31 December 2023. During the last 3 years, it has fallen by -$17.80 million (-68.56%). LPTX annual CFO is now -479.51% below its all-time high of -$7.55 million, reached on 31 December 2012.LPTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$15.60 M
-$1.93 M-14.11%
30 September 2024
Summary:
Leap Therapeutics quarterly cash flow from operations is currently -$15.60 million, with the most recent change of -$1.93 million (-14.11%) on 30 September 2024. Over the past year, it has dropped by -$5.11 million (-48.74%). LPTX quarterly CFO is now -282.58% below its all-time high of $8.54 million, reached on 31 December 2015.LPTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$55.17 M
-$5.11 M-10.21%
30 September 2024
Summary:
Leap Therapeutics TTM cash flow from operations is currently -$55.17 million, with the most recent change of -$5.11 million (-10.21%) on 30 September 2024. Over the past year, it has dropped by -$8.78 million (-18.93%). LPTX TTM CFO is now -2964.83% below its all-time high of -$1.80 million, reached on 31 March 2013.LPTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LPTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.8% | -48.7% | -18.9% |
| 3 y3 years | -68.6% | -92.5% | -81.3% |
| 5 y5 years | -68.1% | -124.2% | -96.6% |
LPTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -68.6% | +10.8% | -92.5% | at low | -81.3% | at low |
| 5 y | 5 years | -68.6% | +10.8% | -297.4% | at low | -130.3% | at low |
| alltime | all time | -479.5% | +10.8% | -282.6% | at low | -2964.8% | at low |
Leap Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$15.60 M(+14.1%) | -$55.17 M(+10.2%) |
| June 2024 | - | -$13.67 M(-11.9%) | -$50.05 M(+7.5%) |
| Mar 2024 | - | -$15.52 M(+49.5%) | -$46.57 M(+6.4%) |
| Dec 2023 | -$43.75 M(-10.8%) | -$10.38 M(-1.0%) | -$43.75 M(-5.7%) |
| Sept 2023 | - | -$10.49 M(+3.0%) | -$46.39 M(-3.7%) |
| June 2023 | - | -$10.19 M(-19.8%) | -$48.15 M(-4.1%) |
| Mar 2023 | - | -$12.70 M(-2.4%) | -$50.23 M(+2.4%) |
| Dec 2022 | -$49.04 M(+39.5%) | -$13.01 M(+6.2%) | -$49.04 M(+4.9%) |
| Sept 2022 | - | -$12.25 M(-0.0%) | -$46.75 M(+9.7%) |
| June 2022 | - | -$12.26 M(+6.4%) | -$42.59 M(+11.8%) |
| Mar 2022 | - | -$11.52 M(+7.5%) | -$38.09 M(+8.3%) |
| Dec 2021 | -$35.16 M(+35.4%) | -$10.72 M(+32.3%) | -$35.16 M(+15.5%) |
| Sept 2021 | - | -$8.10 M(+4.5%) | -$30.43 M(+5.2%) |
| June 2021 | - | -$7.75 M(-9.7%) | -$28.92 M(-5.5%) |
| Mar 2021 | - | -$8.59 M(+43.4%) | -$30.62 M(+18.0%) |
| Dec 2020 | -$25.96 M(-3.5%) | -$5.99 M(-9.2%) | -$25.96 M(+0.4%) |
| Sept 2020 | - | -$6.59 M(-30.3%) | -$25.86 M(-1.4%) |
| June 2020 | - | -$9.45 M(+140.7%) | -$26.23 M(+9.5%) |
| Mar 2020 | - | -$3.93 M(-33.4%) | -$23.96 M(-10.9%) |
| Dec 2019 | -$26.90 M(+3.3%) | -$5.89 M(-15.3%) | -$26.90 M(-4.1%) |
| Sept 2019 | - | -$6.96 M(-3.1%) | -$28.06 M(-1.7%) |
| June 2019 | - | -$7.18 M(+4.6%) | -$28.55 M(+4.1%) |
| Mar 2019 | - | -$6.87 M(-2.6%) | -$27.42 M(+5.3%) |
| Dec 2018 | -$26.03 M | -$7.05 M(-5.4%) | -$26.03 M(+2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$7.45 M(+23.1%) | -$25.35 M(+25.2%) |
| June 2018 | - | -$6.05 M(+10.5%) | -$20.26 M(-4.7%) |
| Mar 2018 | - | -$5.48 M(-14.0%) | -$21.27 M(-3.9%) |
| Dec 2017 | -$22.14 M(-12.6%) | -$6.37 M(+170.2%) | -$22.14 M(-4.0%) |
| Sept 2017 | - | -$2.36 M(-66.6%) | -$23.07 M(-17.9%) |
| June 2017 | - | -$7.06 M(+11.2%) | -$28.08 M(+1.9%) |
| Mar 2017 | - | -$6.35 M(-13.0%) | -$27.55 M(+8.7%) |
| Dec 2016 | -$25.34 M(+212.7%) | -$7.30 M(-1.0%) | -$25.34 M(+166.8%) |
| Sept 2016 | - | -$7.37 M(+12.8%) | -$9.50 M(+26.8%) |
| June 2016 | - | -$6.54 M(+58.1%) | -$7.49 M(+13.6%) |
| Mar 2016 | - | -$4.13 M(-148.4%) | -$6.59 M(-18.6%) |
| Dec 2015 | -$8.10 M(-55.0%) | $8.54 M(-259.3%) | -$8.10 M(-63.7%) |
| Sept 2015 | - | -$5.36 M(-5.0%) | -$22.30 M(+1.1%) |
| June 2015 | - | -$5.64 M(0.0%) | -$22.05 M(+6.4%) |
| Mar 2015 | - | -$5.64 M(-0.1%) | -$20.72 M(+15.0%) |
| Dec 2014 | -$18.02 M(+81.3%) | -$5.65 M(+10.5%) | -$18.02 M(+11.5%) |
| Sept 2014 | - | -$5.11 M(+18.4%) | -$16.16 M(+24.4%) |
| June 2014 | - | -$4.32 M(+47.0%) | -$12.99 M(+17.3%) |
| Mar 2014 | - | -$2.94 M(-22.6%) | -$11.08 M(+11.4%) |
| Dec 2013 | -$9.94 M(+31.6%) | -$3.80 M(+95.8%) | -$9.94 M(+61.8%) |
| Sept 2013 | - | -$1.94 M(-19.3%) | -$6.14 M(+46.1%) |
| June 2013 | - | -$2.40 M(+33.6%) | -$4.20 M(+133.6%) |
| Mar 2013 | - | -$1.80 M | -$1.80 M |
| Dec 2012 | -$7.55 M | - | - |
FAQ
- What is Leap Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Leap Therapeutics?
- What is Leap Therapeutics annual CFO year-on-year change?
- What is Leap Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Leap Therapeutics?
- What is Leap Therapeutics quarterly CFO year-on-year change?
- What is Leap Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Leap Therapeutics?
- What is Leap Therapeutics TTM CFO year-on-year change?
What is Leap Therapeutics annual cash flow from operations?
The current annual CFO of LPTX is -$43.75 M
What is the all time high annual CFO for Leap Therapeutics?
Leap Therapeutics all-time high annual cash flow from operations is -$7.55 M
What is Leap Therapeutics annual CFO year-on-year change?
Over the past year, LPTX annual cash flow from operations has changed by +$5.29 M (+10.79%)
What is Leap Therapeutics quarterly cash flow from operations?
The current quarterly CFO of LPTX is -$15.60 M
What is the all time high quarterly CFO for Leap Therapeutics?
Leap Therapeutics all-time high quarterly cash flow from operations is $8.54 M
What is Leap Therapeutics quarterly CFO year-on-year change?
Over the past year, LPTX quarterly cash flow from operations has changed by -$5.11 M (-48.74%)
What is Leap Therapeutics TTM cash flow from operations?
The current TTM CFO of LPTX is -$55.17 M
What is the all time high TTM CFO for Leap Therapeutics?
Leap Therapeutics all-time high TTM cash flow from operations is -$1.80 M
What is Leap Therapeutics TTM CFO year-on-year change?
Over the past year, LPTX TTM cash flow from operations has changed by -$8.78 M (-18.93%)